Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
OBJECTIVE: The aim of this study was to compare survival outcomes in two groups of patients with recurrent epithelial ovarian cancer (EOC) with initial recurrence detection by cancer antigen 125 (CA-125) elevation or imaging, and underwent secondary cytoreductive surgery (SCS). METHODS: A retrospect...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944013/ https://www.ncbi.nlm.nih.gov/pubmed/27329194 http://dx.doi.org/10.3802/jgo.2016.27.e46 |
_version_ | 1782442690597617664 |
---|---|
author | Paik, E Sun Kim, Tae-Joong Lee, Yoo-Young Choi, Chel Hun Lee, Jeong-Won Kim, Byoung-Gie Bae, Duk-Soo |
author_facet | Paik, E Sun Kim, Tae-Joong Lee, Yoo-Young Choi, Chel Hun Lee, Jeong-Won Kim, Byoung-Gie Bae, Duk-Soo |
author_sort | Paik, E Sun |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to compare survival outcomes in two groups of patients with recurrent epithelial ovarian cancer (EOC) with initial recurrence detection by cancer antigen 125 (CA-125) elevation or imaging, and underwent secondary cytoreductive surgery (SCS). METHODS: A retrospective review of the medical records was performed on 99 recurrent EOC patients who underwent SCS at the Samsung Medical Center between January 2002 and December 2013. For follow-up after primary treatment, patients were routinely assessed by CA-125 levels every 3 months and computed tomography (CT) scan (or magnetic resonance imaging [MRI]) every 6 months for first 3 years, and by CA-125 every 6 months and CT scan (or MRI) every 12 months thereafter. RESULTS: The first recurrence was initially identified by either CA-125 elevation (n=41, 41.4%) or by imaging study (n=58, 58.6%). None of the patients showed the symptoms as initial sign of recurrence. There were higher percentages of extra-pelvic recurrence (87.8%) and multiple recurrences (78.0%) in the group diagnosed by CA-125 elevation. The proportion of no residual disease after SCS was comparably lower in the CA-125 group (22.0% vs. 72.4%). There were 19 cancer-associated deaths (19.2%) within a median follow-up period of 67 months. The group diagnosed by imaging had better overall survival from initial diagnosis (OS1), overall survival after SCS (OS2), progression-free survival after the initial treatment (PFS1) and progression-free survival after SCS compared to those of the CA-125 group (PFS2). CONCLUSION: EOC patients with recurrence initially detected by imaging study showed better survival outcomes than patients diagnosed by CA-125 elevation. |
format | Online Article Text |
id | pubmed-4944013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-49440132016-09-01 Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer Paik, E Sun Kim, Tae-Joong Lee, Yoo-Young Choi, Chel Hun Lee, Jeong-Won Kim, Byoung-Gie Bae, Duk-Soo J Gynecol Oncol Original Article OBJECTIVE: The aim of this study was to compare survival outcomes in two groups of patients with recurrent epithelial ovarian cancer (EOC) with initial recurrence detection by cancer antigen 125 (CA-125) elevation or imaging, and underwent secondary cytoreductive surgery (SCS). METHODS: A retrospective review of the medical records was performed on 99 recurrent EOC patients who underwent SCS at the Samsung Medical Center between January 2002 and December 2013. For follow-up after primary treatment, patients were routinely assessed by CA-125 levels every 3 months and computed tomography (CT) scan (or magnetic resonance imaging [MRI]) every 6 months for first 3 years, and by CA-125 every 6 months and CT scan (or MRI) every 12 months thereafter. RESULTS: The first recurrence was initially identified by either CA-125 elevation (n=41, 41.4%) or by imaging study (n=58, 58.6%). None of the patients showed the symptoms as initial sign of recurrence. There were higher percentages of extra-pelvic recurrence (87.8%) and multiple recurrences (78.0%) in the group diagnosed by CA-125 elevation. The proportion of no residual disease after SCS was comparably lower in the CA-125 group (22.0% vs. 72.4%). There were 19 cancer-associated deaths (19.2%) within a median follow-up period of 67 months. The group diagnosed by imaging had better overall survival from initial diagnosis (OS1), overall survival after SCS (OS2), progression-free survival after the initial treatment (PFS1) and progression-free survival after SCS compared to those of the CA-125 group (PFS2). CONCLUSION: EOC patients with recurrence initially detected by imaging study showed better survival outcomes than patients diagnosed by CA-125 elevation. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016-09 2016-05-09 /pmc/articles/PMC4944013/ /pubmed/27329194 http://dx.doi.org/10.3802/jgo.2016.27.e46 Text en Copyright © 2016. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Paik, E Sun Kim, Tae-Joong Lee, Yoo-Young Choi, Chel Hun Lee, Jeong-Won Kim, Byoung-Gie Bae, Duk-Soo Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer |
title | Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer |
title_full | Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer |
title_fullStr | Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer |
title_full_unstemmed | Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer |
title_short | Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer |
title_sort | comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944013/ https://www.ncbi.nlm.nih.gov/pubmed/27329194 http://dx.doi.org/10.3802/jgo.2016.27.e46 |
work_keys_str_mv | AT paikesun comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer AT kimtaejoong comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer AT leeyooyoung comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer AT choichelhun comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer AT leejeongwon comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer AT kimbyounggie comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer AT baeduksoo comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer |